Pfizer, like some other big drug makers, is facing tepid growth amid generic competition and the lack of clear blockbusters in its drug pipeline.

• 和其它大型制药企业一样，辉瑞也面临着因普通药物的竞争而导致的业务增长缓慢，同时它研制的药物中尚缺乏能带来巨大效益的轰动性药物。